Professor Nancy Klimas om Rituximab-studien

Posted on 21/11/2011


Professor Nancy Klimas er et kjent navn i ME-forskningen. Hun sier følgende om resultatene fra Rituximab-studien:

“The recent study of  Drs. Øystein Fluge and Olav Mella demonstrating significant improvement in ME/CFS patients treated with the B cell depleting agent Rituximab is a key study for our field.

By showing that depleting B cells can cause dramatic improvement, the investigators point the field in the direction of autoimmunity, and autoimmunity caused by an autoantibody.  However, there is one other plausible explanation: that  the B cells were acting as a reservoir of infection and by depleting the B cell line the viral load can be brought down to the point of suppression by the  immune system.  Because EBV infection is harbored by B cells, as are several other putative latent viruses that could contribute to illness persistence, I believe both of these theories deserve vigorous scientific pursuit.

Many clinicians fail to realize the severity of the illness that has been termed ME/CFS.   This is a profoundly ill population, the severity of illness scores are similar to congestive heart failure and severe rheumatic disorders such as rheumatoid arthritis.  If a medication like Rituximab is found to be effective in validation studies, the risk/benefit ratio would justify its use in very ill ME/CFS patients.”

Hentet fra Bergen Teknologioverføring – les hele innlegget her.

Bergen Teknologioverføring har også en samleside om saken her. 

Posted in: Forskning